AI and Ozempic

AI is likened to GLP-1 drugs, both serving to suppress cravings and reshape industries while exacerbating existing inequities. The hesitance to admit reliance on these innovations mirrors societal pressures around self-control and success. Interestingly, the regions with the highest usage of GLP-1 drugs are often the thinnest, highlighting a disconnect in access and need. The potential public health and economic benefits of these technologies are immense, yet they remain out of reach for many who could benefit the most.